New

Create, analyze, optimize your ETF portfolio. Start now →

Advertisement
Advertisement

XPHvsETF 2ETF Comparison

ETF 1
XPH

State Street SPDR S&P Pharmaceuticals ETF

This fund is part of
US Health Care
-1.08%
VS
ETF 2
Suggested XPH comparisons

Choose a second ETF to run a side-by-side ETF comparison with XPH, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

XPH performance and flow charts

Performance

0510%Mar 24Mar 31Apr 8Apr 15Apr 22

Cumulative Flows

0 M5 M10 M15 M20 M25 MMar 24Mar 31Apr 8Apr 15Apr 22

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 04/24/2026
1M3MYTD1Y3Y5Y
Perf.
XPH
ETF 2
+9.68%
+2.44%
+2.61%
+44.99%
+40.83%
+22.16%
Flows
XPH
ETF 2
+$25M
+$82M
+$116M
+$141M
+$48M
+$64M
Volatility and drawdown
3M1Y3Y5Y
Volatility
XPH
ETF 2
+24.78%
+21.12%
+19.49%
+20.45%
Max drawdown
XPH
ETF 2
-11.78%
-11.78%
-23.45%
-31.59%
Max drawdown duration
XPH
ETF 2
50d
50d
322d
1566d
Trading data

Create an account to view trading data

Join for free
XPH
ETF 2
Last sale
4/24/2026 at 1:30 PM
$57.40
Previous close
04/23/2026
$57.20
Consolidated volume
04/23/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of March 31, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

Create an account to view replication quality

Join for free
XPH
ETF 2
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 4/24/2026 at 1:30 PM
Live
Closed
XPH
ETF 2
Last price
$57.40
1D performance
+0.35%
AuM$353.54 M
E/R0.35%
Characteristics
XPH
ETF 2
Management strategyPassive
ProviderState Street Investment Management
BenchmarkS&P Pharmaceuticals Select Industry Index
N° of holdings48
Asset classEquities
Trailing 12m distribution yield
Join
Join
Inception dateJune 19, 2006
ESGNo
Advertisement
Exposure

Countries

XPH
USA
87.77%
Other
12.23%
ETF 2

Sectors

XPH
Health Care
82.36%
Other
17.64%
ETF 2

Diversification

XPH

Total weight of top 15 holdings out of 15

30.65%
ETF 2

Top 15 holdings

Data as of March 31, 2026
XPH
US29337E1029
2.45%
CORCEPT THERAPEUTICS
2.29%
TERNS PHARMACEUTICALS
2.16%
PERRIGO CO PLC
2.10%
AXSOME THERA CMN STK
2.03%
INNOVIVA INC
1.99%
MERCK & CO INC
1.98%
PFIZER
1.97%
ROYALTY PHARMA
1.97%
ELANCO ANIMAL HEALTH INC
1.96%
JAZZ PHARMACEUTICALS
1.96%
ESPERION THERAPEUTICS
1.95%
EDGEWISE THERAPEUTICS
1.95%
US55287L1017
1.95%
BRISTOL-MYERS SQUIBB
1.94%
ETF 2
Advertisement
Advertisement
Advertisement
Webcast on Demand

Calamos Investments Powers the Next Phase of the Autocallable Revolution

Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.

Accepted for 1 CE Credit

Calamos Webcast